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Aldosterone is a homeostatic hormone, rising in volume depletion, sodium deficiency, 
and potassium loading, in response to angiotensin11 and elevation of plasma potassium. 
Pathophysiologically, in primary aldosteronism (PA) aldosterone levels are inappropriate 
for the patient’s sodium and potassium status, and thus outside the normal feedback 
loop. ACTH is equivalent with A11 and [K+] in elevating aldosterone: its effects differ from 
those of the other secretagogues in four ways. First, it is not sustained; second, it raises 
aldosterone and cortisol secretion with equal potency; third, it is outside the normal 
feedback loops, reflecting the epithelial action of aldosterone; and finally its possible 
role in driving inappropriate aldosterone secretion (aka PA) is not widely recognized. 
Thirty years ago, it was shown that on a fixed sodium intake of 175 meq/day 36 of 100 
unselected hypertensives, in whom PA has been excluded on contemporary criteria, 
had 24  h urinary aldosterone levels above the upper limit of normotensive controls. 
More recently, the dexamethasone enhanced fludrocortisone suppression test (FDST) 
showed 29% of unselected hypertensives to have plasma aldosterone concentrations 
above the upper limit of normotensive controls. In subjects negative for PA on the FDST, 
27% were extremely hyper-responsive to ultra-low dose ACTH infusion; the remaining 
73% showed minimal aldosterone elevation, as did normotensive controls: all three 
groups had negligible cortisol responses. On treadmill testing, no differences were found 
between groups in (minimally altered) ACTH and cortisol levels: hyper-responders to 
ultra-low ACTH, however, showed a major elevation in PAC. The implications of these 
studies, when validated, are substantial for PA, in that approximately half of hypertensive 
patients appear to show inappropriate aldosterone levels for their sodium status. The 
physiological role(s) of ACTH as an acute aldosterone secretagogue, and the mecha-
nisms whereby its continuous secretion is curtailed, remain to be established.
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BAcKGrOUND
For many years, most studies on aldosterone have focused on its action on renal salt and water 
transport, undeniably its major homeostatic role. More recently, following the RALES trial of the 
effects of spironolactone in progressive cardiac failure (1), a range of extraepithelial effects, primarily 
cardiovascular, has been shown in animal studies (2–4). The doses of aldosterone (or DOCA) used, 
and the extent of salt loading, make extrapolation to physiology difficult, and to human pathophysi-
ology doubly difficult. That said, PA clearly has a higher cardiovascular risk profile than age-, sex-, 
and blood pressure-matched essential hypertension (EH) (5, 6): whether this is a primary effect of 
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aldosterone on the heart and/or blood vessels, or secondary to the 
increased total body sodium, is yet to be established (7).
The secretory response to what are commonly regarded as its 
principal regulators (angiotensin II, plasma potassium concen-
tration) is prolonged as long as the stimulus persists. In contrast, 
ACTH elevates aldosterone acutely but transiently. At least two 
features of this response are unclear. The first is the organ(s) 
and processes targeted by the acute elevation; the second the 
mechanism(s) whereby this acute response is curtailed. Given 
that the circadian rhythm of aldosterone secretion clearly pre-
cedes that of cortisol, both steroids may have roles as “Zeitgebers,” 
effecting diurnal changes in their respective physiologic target 
tissues. In addition to its circadian variation, however, ACTH 
is elevated by stress, physical, or psychological. Whereas stress 
responses to elevated cortisol have been widely studied, those 
in response to elevated aldosterone appear to have escaped 
attention. It may be that they form part of the classical “fight or 
flight” response, by acutely (non-genomically) activating min-
eralocorticoid receptors (MR) in the vasculature, a physiologic 
aldosterone target tissue expressing the specificity-conferring 
enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) 
(8). A similar rapid vasoconstrictor response follows the acute 
aldosterone elevation upon orthostasis.
What curtails the elevation of aldosterone secretion despite 
continued high ACTH levels is currently unclear. One attractive 
possibility is that it reflects a genomic effect of maintained high 
levels of glucocorticoid secretion. Heterozygous glucocorticoid 
receptor (GR) (±) null mice show persistently elevated levels 
of both corticosterone and aldosterone levels, consistent with 
elevated levels of ACTH and impaired glucocorticoid negative 
feedback on aldosterone secretion (9). To date, there appear to be 
no reports on levels of aldosterone in patients with hypercorti-
solism due to GR abnormalities leading to increased ACTH lev-
els. There are, of course, additional/other mechanisms whereby 
the acute elevation of aldosterone in response to ACTH might 
be curtailed.
Finally, it is accepted that under normal circumstances, ACTH 
acts with equivalent potency as a secretagogue for cortisol and 
aldosterone. Recently, as will be discussed in detail below, there 
is evidence that aldosterone secretion appears supersensitive 
to very low dose ACTH at levels which do not elevate cortisol 
secretion (10).
PriMArY ALDOsterONisM
The first description of the role of ACTH came over 50 years ago, 
with the description by Sutherland et al. of a patient with “hyper-
tension, increased aldosterone secretion and low plasma renin 
activity relieved by dexamethasone” (11). This constellation, 
variously termed glucocorticoid-suppressive hyperaldosteronism 
(GSH) or glucocorticoid-remediable aldosteronism (GRA) is 
now termed familial hyperaldosteronism Type-1, and its genesis 
demonstrated in an early paper from the Lifton laboratory (12). 
This heritable condition reflects a crossover event during ances-
tral meiosis, wherein a chimeric gene with the 5′ end of CYP11 
B1 (11β hydroxylase) and the 3′ end of CYP11 B2 (aldosterone 
synthase) are fused. This results in a sequence, which is expressed 
throughout the zona fasciculata, producing high levels of aldos-
terone in response to normal levels of ACTH, rather than the nor-
mally much lower levels from aldosterone producing cell clusters 
(13) in the zona glomerulosa. Suppression of ACTH secretion by 
dexamethasone lowers aldosterone levels and replaces (more or 
less) the secretion of endogenous glucocorticoid.
Arguably, the first of the studies directly addressing the poten-
tial role of ACTH in PA was by Kem et al. (14). Seven PA patients 
[three ideopathic adrenal hyperplasia (IAH) and four aldosterone 
producing adenoma (APA)] were studied, with the conclusion 
that “these data indicate that ACTH frequently is the dominant 
stimulus of the episodic secretion of aldosterone in patients with 
either adrenal adenomas or hyperplasia.” Couple this with a 
report 4 years later by Helber et al. (15) entitled “Evidence for a 
subgroup of essential hypertensives with non-suppressible excre-
tion of aldosterone during sodium loading.” The effect of sodium 
loading (175 μg/day for 6 days) on 24 h urinary aldosterone (UA) 
was determined in three groups – 56 healthy controls, 100 patients 
with EH, and 16 patients with PA (12 APA, 4 IAH). In healthy 
controls, the upper limit of UA was <6 μg/day; all the PA patients 
were unsuppressed (IAH 8–20, APA 23–64 μg/day); 64 of the EH 
patients suppressed UA to levels in the normal range; but 36 did 
not, with values above 6 and up to 16 μg/day. Non-suppressing 
EH patients showed a mean UA value of 10 ±  3 (SD) μg/day; 
those who suppressed a mean of 2.7 ±  1.4 (SD). Plasma [K+] 
in the 36 non-suppressors was 3.81 ± 0.44 meq/L and in the 64 
EH suppressors was 4.26 ± 0.37 meq/L (p < 0.001). Finally, in 
response to 4 weeks on 200 mg/day spironolactone, blood pres-
sure fell by 22 mmHg in non-suppressors, 21 mmHg in the PA 
patients, and 9  mmHg in the 64 EH patients who suppressed. 
The authors conclude, “We believe, therefore, that our patient 
groups with inadequate high aldosterone suppression during Na+ 
loading may reflect qualitatively a similar pathogenetic defect 
in mineralocorticoid secretion as “hyperplasia patients” with 
hypermineralocorticoidism.”
These data, based on 24  h urinary rather than spot plasma 
aldosterone, remained unremarked for more than three decades. 
By the use of variously stringent cut-offs in both the screening test 
for aldosterone [the aldosterone to renin ratio (ARR)] followed 
by confirmatory testing, PA is currently gazetted to affect 5–13% 
of referred hypertensives. Add the 16 confirmed PA to the 36 
non-suppressors found by Helber et al. in patients referred to the 
University of Cologne, and the figure stands at 45%, which would 
currently be regarded as totally out of court, given the under-
standable focus on the most florid expression of PA, sometimes 
dubbed “low hanging fruit.”
Where this at face value improbable figure starts to make 
sense is the incorporation of ACTH status into confirmatory/
exclusion testing. Currently, any one of half a dozen procedures 
are used around the world, of which the fludrocortisone-saline 
suppression test (FST) is sometimes regarded as the “gold 
standard” – 4 days of fludrocortisone, sodium, potassium sup-
plementation, and often (but not always) hospitalization. In a 
series of papers from the Piaditis group in Athens (10, 16–19), 
the potentially confounding effect of ACTH on values obtained 
in the FST has been addressed in two ways. First is the inclusion 
of 2  mg dexamethasone at midnight on the last day of testing 
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[fludrocortisone suppression test (FDST)], with initial results 
that were arresting, in both a group of control normotensives 
with normal adrenals on imaging, and a second group of essen-
tially unselected hypertensives (16).
On the FDST, the 97.5% upper limit of normal for plasma 
aldosterone concentration (PAC) was found to be 74 pmol/L, and 
for ARR 32 pmol/mL, in the 72 normotensive controls. Among 
the 180 hypertensives, 56 (31%) showed upright PAC values 
above 74 pmol/L, combined with an ARR >32 pmol/mU on day 
5, evidence for a much higher percentage of unselected hyperten-
sives having inappropriate aldosterone secretion, i.e., PA. In prior 
studies from the same group, the classical saline infusion test 
(SIT) was compared with a post-dexamethasone SIT; the latter 
showed a similar (24%) prevalence of PA, more than double the 
11% found on the commonly used SIT (17). More recently, much 
larger groups of controls (n = 100) and hypertensives (327) have 
been studied, with results essentially identical to the initial study, 
and a prevalence of PA of 29% (18). A recent overview by Piaditis 
and colleagues (19) compares these latter figures for prevalence 
with those from other centers absent dexamethasone loading, 
which range from 1 to 18%.
There are a number of factors that may conspire toward 
explaining the difference with and without dexamethasone. The 
first is the reliance on plasma cortisol as a surrogate for ACTH: 
just as their circadian secretion appears different, the responses to 
stress (see below) may differ. Second is the single make-or-break 
value for PAC, close to the nadir of circadian levels, on which both 
screening (ARR, PAC above some arbitrary cut-off) depend. It is 
just possible that Helber et al. got it right, and that UA integrates 
secretion over 24  h, which may be more pathophysiologically 
relevant. Finally, it may be that in the historically nephrocentric 
universe of stimuli to aldosterone secretion angiotensin II reigns 
supreme, plasma [K+] admitted almost as an afterthought, and a 
continuous role of ACTH almost entirely neglected. We may have 
to extend the sentence quoted earlier from Kem et al. “These data 
indicate that ACTH frequently is the dominant stimulus of the 
episodic secretion of aldosterone in patients with either adrenal 
adenomas or hyperplasia” (14) from the pathophysiological to 
the realm of physiology, in control normotensives [to halve the 
97.5% cut-off in the FST (6 meq/L) to 3 meq/L in the FDST], and 
(incidentally) in only ~70% of essential hypertensives.
There would also appear to be another dimension in which 
ACTH may be a probable actor in inappropriate hypersecretion 
of aldosterone. The data also come from the Athens group, and 
address patients with EH who previously tested negative for PA 
by the FDST. In this study (10), 113 of such hypertensives and 
61 normotensive controls underwent an ultra-low dose ACTH-
stimulation test, followed by a treadmill test. On the basis of 
the cut-off values for aldosterone (47 ng/dL) and ARR (2.7 ng/
dL/μU/mL) at 15- or 30-min post ACTH (97.5% percentile value 
in controls), 30/113 (27%) of hypertensives recorded values for 
both PAC and ARR above the cut-off (HYPER group), and 83/113 
(73%) did not (EH: ESHT group). Mean values for aldosterone 
post-ACTH were identical in the control and ESHT groups, and 
approximately threefold higher at both 15 and 30  min in the 
HYPER group; cortisol levels post-ACTH were the same in all 
three groups.
The authors then extended their studies from testing the 
adrenal responses to ultra-low ACTH to real life (more or less), 
with all participants undergoing a treadmill stress test to 80% 
of age-adjusted maximal cardiac pulse, 24 h after the ultra-low 
ACTH test in each project. When the results of both tests were 
aggregated and analysed, the 30 patients in the HYPER group 
showed a twofold to threefold greater elevation over baseline 
compared with controls or ESHT: no group showed an elevation 
in plasma cortisol at peak or recovery.
These studies are prismatic, but not perfect. In addition 
to issues canvassed in the accompanying editorial (20), other 
questions might be raised. Variances for all groups in terms 
of response to ultra-low ACTH are extraordinarily low, even 
when expressed as they are at SEM; this is much less the case 
for aldosterone responses to treadmill testing, but those for 
the other two groups remain tight. In contrast, the variances 
in terms of cortisol response are enormous. The FDST test 
was done on days 4–7, after ultra-low ACTH on day 2 and the 
treadmill on day 3. While this may have been convenient, it 
presumably excluded an unspecified number of subjects who 
had undergone the two previous tests. There would thus appear 
to be a corpus of data on such subjects, in addition to the 113 
hypertensives who “failed” the FDST. From this perspective, 
these patients may have been of more interest than the adventi-
tious KCNJ5 data.
These questions said and done, the data from these studies 
(10,  16–19) taken together argue powerfully that we need to 
reconsider our currently accepted values for the prevalence of 
inappropriate aldosterone secretion (aka PA). The current figures 
of 1–18% of hypertension – on the basis of strict or relaxed cut-offs, 
referred or general practice patients – are testimony to diagnostic 
frailty rather than variation in patient populations: what the first 
three of the Athens studies have shown is a potential confounder 
in unrecognized roles for ACTH in testing. The implication of the 
three studies (16–18) is that ~ 30% of unselected hypertensives 
have autonomous aldosterone secretion independent of the 
classic secretagogues, a much higher figure than is currently 
acknowledged.
The ultra-low ACTH/treadmill studies open a quite distinct 
scenario, that of heightened zona glomerulosa sensitivity to eve-
ryday stresses, accounting for a similar fraction of hypertensive 
subjects. Just as the driver of PA is unclear in the majority of 
PA diagnosed post-FDST, so it is for the genesis of the adrenal 
sensitivity. What needs to be done is to validate the generaliz-
ability of past findings, not by slavishly repeating the present 
protocols, given the difficulty in persuading control subjects 
to undergo imaging and FDST, but by doing a comparison of 
the seated saline suppression test (SSST) with and without 
2 mg dexamethasone at midnight on the day before (FSSST). In 
preliminary studies, Michael Stowasser’s laboratory has shown 
excellent comparability between the SSST and the FST (21). 
Subjects negative on the FSSST might then be enrolled in an 
ultra-low dose ACTH study, including if possible a 24 h urine to 
measure integrated aldosterone secretion, in addition to values 
obtained during the test.
If, as I anticipate, this series of findings from Athens can be 
generalized, we need to recognize that PA affects not ~ 10% 
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of hypertensives but over half. Currently, major interest and 
considerate resources are devoted to seeking, for example, addi-
tional somatic mutations possibly involved in oversecretion of 
aldosterone from APA: it may be much less fun grinding through 
clinical studies, but the outcome for hypertensive patients is likely 
to be far greater. If over half of hypertensive patients have PA, 
and fewer than 1% are even screened let alone diagnosed and 
treated in any jurisdiction, the case for inclusion of low dose MR 
antagonist in first line antihypertensive therapy would appear to 
be incontrovertible.
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